LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hello fellow warriors! Some exciting news and noteworthy updates this week. And the pace of prostate cancer research shows no signs of slowing down!
Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.

Clinical Research

• Phase 1 Trial: Pasritamig + JNJ-87189401 Dual T-Cell Engagement
  ​Early Phase 1 clinical trial results presented at SITC 2026 evaluated a novel dual-target immunotherapy combining pasritamig (a KLK2×CD3 T-cell engager) and JNJ-87189401 (a PSMA×CD28 costimulatory antibody) in heavily pretreated metastatic castration-resistant prostate cancer (mCRPC). Among 15 patients treated at the recommended dose, 73.3% achieved a PSA reduction of at least 50% (PSA50), 46.7% achieved a PSA90 reduction, and 26.7% reached undetectable PSA levels below 0.2 ng/mL. No grade 3 or higher treatment-related adverse events occurred at the recommended dose.
  ​
• Phase 1 Trial: First Patient Dosed with Dual-Target ICP-B381 Antibody-Drug Conjugate
  ​A Phase 1 clinical trial has dosed its first patient in China to test ICP-B381, an experimental bispecific antibody-drug conjugate (ADC) designed to simultaneously target PSMA and STEAP1 using an irreversible linker to combat tumor heterogeneity in advanced prostate cancer and other solid tumors. In preclinical 22Rv1 xenograft models, ICP-B381 demonstrated 94% tumor-growth inhibition at 1 mg/kg, outperforming single-target STEAP1 (81%) and PSMA (73%) ADCs in tumors expressing lower target antigen levels.
  ​
• Phase 2 Trial: ctDNA Liquid Biopsy to Identify Candidates for Targeted Radiotherapy
  ​A prespecified secondary analysis of the Phase 2 TRAP trial published in JAMA Network Open demonstrated that circulating tumor DNA (ctDNA) can identify oligoprogressive mCRPC patients who derive prolonged benefit from stereotactic body radiotherapy (SBRT). Patients testing ctDNA-negative before radiotherapy achieved a median progression-free survival of 7.8 months compared to 3.0 months in ctDNA-positive patients (HR 2.18), as well as a significantly longer median time to next systemic therapy or death (29.6 vs. 15.3 months).
  ​
• Phase 2 Trial: Ifinatamab Deruxtecan (I-DXd) in Neuroendocrine Prostate Cancer
  ​A multicenter Phase 2 clinical trial is evaluating ifinatamab deruxtecan (I-DXd),a B7-H3 (CD276)-targeted ADC delivering a topoisomerase I inhibitor payload, in 30 patients with metastatic neuroendocrine prostate cancer (NEPC). The trial evaluates both de novo NEPC and treatment-emergent neuroendocrine transformation, utilizing broad inclusion criteria based on neuroendocrine histology/markers or key genomic alterations (RB1, TP53, PTEN) to measure objective response rates (ORR), ctDNA dynamics, and B7-H3 expression.
  ​
• Phase 2 Trial: FDA Grants Breakthrough Therapy Designation to ⁶⁴Cu-SAR-bisPSMA PET Imaging
  ​The FDA granted Breakthrough Therapy designation to ⁶⁴Cu-SAR-bisPSMA, making it the first PSMA PET imaging agent to receive this status for detecting recurrent prostate cancer following PSA elevation. The designation was supported by the Phase 2 Co-PSMA trial, where ⁶⁴Cu-SAR-bisPSMA detected 63 lesions compared to 24 with standard ⁶⁸Ga-PSMA-11 (78% vs. 36% detection rate) in patients with biochemical recurrence, while Phase 3 registration trials (AMPLIFY and CLARIFY) have completed recruitment.
  ​
• American Cancer Society Updates Prostate Cancer Screening Guidelines
  ​Published on November 12, 2026, the American Cancer Society released its first major prostate cancer screening guideline update since 2010, recommending biennial PSA screening for average-risk men aged 50–69 and annual screening starting at age 45 for Black men and men with a strong family history. The updated guidelines advise that elevated PSA levels (≥3 ng/mL under age 70) should be confirmed by repeat testing within two weeks to three months and evaluated with prostate MRI or biomarkers prior to biopsy, alongside advocating active surveillance for low-risk disease.
  ​
• Metastasis-Directed Radiotherapy for Oligoprogressive Castration-Resistant Prostate Cancer
  ​A retrospective study published in the Japanese Journal of Clinical Oncology analyzed 43 oligoprogressive CRPC patients treated with metastasis-directed radiotherapy (MDRT), demonstrating a median progression-free survival of 9.0 months and PSA50 reductions in 53% of patients. Among 13 patients undergoing a second course of MDRT for subsequent oligoprogression, a median secondary progression-free survival (PFS2) of 14.0 months was achieved without any grade 3 or higher treatment-related adverse events.

Preclinical Research & Reviews

• Reversing Treatment Resistance via Specific tRNA Restoration
  ​A preclinical study published in Nature revealed that reduced expression of a specific transfer RNA, tRNAArg(UCU)-1, promotes androgen independence and resistance to androgen receptor (AR)-targeted therapies by altering chromatin-remodeling proteins such as SMARCC2. Restoring tRNAArg(UCU)-1 or SMARCC2 recovered AR signaling and restored treatment sensitivity in experimental models, while lower tRNA levels in patient tumors correlated with neuroendocrine differentiation, earlier metastasis, and poorer survival.​
  ​

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max